ESCRS - FP11.12 - Drug-Repository Contact Lens For Prolonging The Antimicrobial- Cornea Interaction For Bacterial Keratitis Treatment: Randomized Controlled Trial Results

Drug-Repository Contact Lens For Prolonging The Antimicrobial- Cornea Interaction For Bacterial Keratitis Treatment: Randomized Controlled Trial Results

Published 2024 - 42nd Congress of the ESCRS

Reference: FP11.12 | Type: Free paper | DOI: 10.82333/bp3v-2990

Authors: Lional Raj Daniel Raj Ponniah* 1

1Department of Cornea,Dr. Agarwal's Eye Hospital,Tirunelveli,India

Purpose

Microbial keratitis can cause unilateral blindness, but the drug delivery treatment options are poor. Therefore, this study evaluated the efficacy of a novel therapeutic drug-depository contact lens (DDCL) for bacterial keratitis (BK) treatment. The lens was designed to increase the corneal lesion-antimicrobial drug interaction time.

Setting

An open-labelled randomized controlled study to compare topical antimicrobial administration and antimicrobial administration with DDCLs for treating BK. The study was conducted at the Cornea and Ocular Surface Diseases Clinic at a Tertiary Eye Hospital and Research Institute in Tirunelveli, South India.

Methods

Bacterial Keratitis (BK) patients were randomized (1:1) into two groups: topical antimicrobial treatment only (Group 1) and DDCL plus antimicrobial treatment (Group 2). Both groups received 0.5 % moxifloxacin. We evaluated BK recovery, anterior chamber (AC) reactions, corneal haze and
pain (on a 10-point scale) 12 hours and 1, 3, 5, and 14 days after treatment.

Results

The baseline corneal-infiltration (i.e., BK severity) values were comparable for Groups 1 (18 cases) and 2 (17 cases) (P = 0.92). After 12 hours, the scores improved in both groups and continued to improve throughout the follow-up period; the improvements were more pronounced in Group 2 than in Group 1 (all P <0.05). Complete recovery occurred on Days 14 and 5 in Groups 1 and 2, respectively. Furthermore, the AC reaction was resolved by Day 3 in Group 2. The baseline pain scores were also comparable between Groups 1 and 2 (P = 0.52) and decreased throughout the follow-up period (all P <0.05); the decrease was more pronounced in Group 2.

Conclusions

Novel DDCLs augment the drug-lesion interaction time by prolonging corneal antimicrobial availability, which hastens corneal healing in BK. Thus, a DDCL may decrease the antibiotic regimen and improve patient tolerance, eliminating the necessity for a loading dose.